Utah Medical Products Inc. has successfully completed its tender offer, purchasing a total of 327,740 shares of its common stock at a price of $75.00 per share. This significant move demonstrates the company's commitment to enhancing shareholder value and optimizing its capital structure.

The tender offer, which was initiated on September 24, 2026, allowed the company to buy back up to 650,000 shares. The offer expired on October 27, 2026, and the total cost for the shares purchased amounted to $24,580,500. Following this transaction, Utah Medical Products has 2,849,041 shares remaining outstanding, which includes 1,775 employee option shares that were exercised in October.

Background

Utah Medical Products Inc. operates in the surgical and medical instruments & apparatus sector, classified under SIC code 3841. The company is listed on the Nasdaq under the ticker symbol UTMD. Utah Medical Products focuses on developing, manufacturing, and marketing a wide range of disposable and reusable specialty medical devices, particularly aimed at improving healthcare for women and their babies.

What the Filing Says

The recent filing indicates, "The Offer expired on Tuesday October 27, 2026. A total of 327,740 shares were purchased by the Company for $75.00/share to stockholders." Additionally, the company incurred $107,720 in administration fees and $6,732 in filing fees to the SEC, leading to an effective cost of $75.35 per share. Furthermore, the federal government will impose a 1% excise tax on share repurchases under the Inflation Reduction Act of 2022.

Impact

This tender offer may impact various stakeholders, including shareholders who participated in the buyback, as well as employees holding stock options. The move also reflects the company's strategy to manage its equity and may influence investor sentiment in the surgical and medical instruments industry.

What's Next

The filing does not say what happens next.